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Abstract
Replication-defective (E1-E3 deleted) adenovirus vector based gene delivery results in the
induction of cytokines including IL-8, which may contribute to the development of inflammatory
immune responses. Like other adenoviruses, E1 + E3 deleted porcine adenovirus (PAdV) 3 induces
the production of IL-8 in infected cells. In contrast, no IL-8 production could be detected in cells
infected with wild-type or mutant PAdV-3s containing deletion in E1A + E3 (PAV211) or E1Bsmall +
E3 (PAV212). Expression of PAdV-3 E1Blarge inhibited the NF-κB dependent transcription of
luciferase from IL-8 promoter. Imunofluorescence and electrophoretic mobility shift assays
suggested that constitutive expression of PAdV-3 E1Blarge inhibited the nuclear translocation of NF-
κB and its subsequent binding to DNA. These results suggest that E1Blarge interacts with NF-κB to
prevent transcription and down regulate proinflammatory cytokine IL-8 production.
Background
Cytokines are important mediators of inflammation and
regulators of the immune response. The inflammatory
response including release of inflammatory cytokines is
the first defense against viral infection. However, viruses
have evolved a number of different strategies to avoid the
host inflammatory responses. Large DNA viruses includ-
ing poxviruses and herpes viruses [1-6] modulate cytokine
action by encoding secreted forms of receptors for
cytokines and chemokines. Adenoviruses modulate
cytokine expression by encoding intracellular proteins,
which counteract TNF-α [7,8].
Although human adenovirus (HAdV) vectors have been
utilized for gene transfer for functional studies in vivo
[9,10], their therapeutic use in delivering genes to the air-
ways of humans is limited due to the transient gene
expression [11]. Earlier studies have shown that the air-
way administration of adenovirus vector results in the
induction of non specific host responses consisting in part
of neutrophil accumulation followed by mononuclear
cell and macrophage accumulation. Adenovirus vector
infection of airway epithelial A549 cells [12,13] or airways
of macaques [14] results in rapid induction of the inflam-
matory cytokine IL-8, which may contribute to the inflam-
matory host response [12]. This induction of IL-8
production has been shown to be due to adenovirus
induced activation of Raf/MAPK pathway [15]. Thus,
blocking these pathways may be required for developing
an efficient adenovirus vector.
Porcine adenovirus (PAdV) 3, a non human adenovirus is
being developed as a vector for gene delivery in animals
and humans [16,17]. Availability of the complete nucle-
otide sequence and transcription map of PAdV-3 [18]
genome has facilitated the construction of recombinant
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PAdV-3s [16,17,19,20] and their use as vaccine delivery
vehicles [21]. Earlier, analysis of early region 1 (E1) of
PAdV-3 suggested that while E1A [20] and E1Blarge [19] are
essential for virus replication, E1Bsmall is not essential for
virus replication [20]. Here, we report that E1Blarge can
impair the induction of inflammatory cytokine IL-8 by
inhibiting the NF-κB dependent gene transcription.
Results and discussion
RNase protection assay
Earlier, induction of chemokines has been reported in
adenovirus vector infected mouse renal epithelial cells
[22], A549 cells [12] and HeLa cells [15], but not in U373
cells [7]. Moreover, both E1A and E3 gene products have
been shown to down regulate the transcription of some
chemokines [7,23]. To determine the effect of PAdV-3 E1
proteins on the induction of chemokines, HeLa cells were
infected with PAV211 (E1A nt [530–1230] + E3 [nt
28112–28709] deleted), PAV212 (E1B small [nt 1460–
1820] + E3 [nt 28112–28709] deleted), PAV227 (E1A +
E1Bsmall + E1Blarge [nt 524–3274] + E3 [nt 28112–28709]
deleted) or PAV300 (E3 [nt 28112–28709] deleted) at an
MOI of 100 infectious units [24]. The construction and
characterization of the mutant PAdV-3s has been
described [19,20]. At 6 h post infection, the cells were har-
vested and processed for the isolation of total RNA using
TRIZOL (Invitrogen) as per manufacturer's protocol.
RNase protection assay was performed with the Ribo-
Quant Muti-Probe template (BD Biosciences) set hCK-5
as per manufacturer's protocol. Autoradiographs were
analyzed by a Molecular phosphoimager FX and Quantity
One software (BIO-RAD). As seen in Fig. 1A, no chemok-
ine specific transcript could be detected in the cells
infected with wild-type or mutant PAdV-3 containing
deletion of E3 (PAV300), E1A + E3 (PAV211) or E1Bsmall
+ E3 (PAV212). Interestingly, IL-8 transcript was the dom-
inant chemokine gene induced in the cells infected with
recombinant PAdV-3 containing deletion of E1A +
E1Bsmall + E1Blarge + E3 (PAV227). These results suggest
that E1Blarge protein inhibit the expression of inflamma-
tory cytokine IL-8.
Luciferase reporter assay
Since increased expression of proinflammatory chemok-
ines including IL-8, in response to various stimuli includ-
ing adenovirus vectors can be upregulated by NF-κB
transcription factor [22], we employed luciferase reporter
assay to examine the inhibition of transcriptional activa-
tion of IL-8 promoter (containing consensus sequence for
NF-κB binding) by E1Blarge protein. As seen in Fig. 1B,
reduced levels of the luciferase activity were obtained
when phIL8-Luc DNA was cotransfected with pCDNA3.1-
pE1BL DNA (expressing E1Blarge). In contrast, significant
levels of luciferase activity were detected when phIL8-Luc
DNA was cotransfected with pCDNA3.1 DNA showing
that the competition for transcription factors binding to
E1Blargeexpression vector did not nonspecifically reduce
the activity of luciferase reporter gene. The results of the
reporter gene expression indicated that E1Blarge reduced
the NF-κB activated gene expression and was responsible
for the observed inhibition of inflammatory cytokine IL-8
production.
E1Blarge inhibits the translocation of NF-κB to the nucleus
NF-κB is a dimmer of two heterologous proteins (p65 and
p50) held in an inactive complex by an endogenous
inhibitor IκB, in the cytoplasm [25]. After cell activation,
IκB is phosphorylated and subsequently degraded releas-
ing NF-κB, which translocates to the nucleus where it
binds to the enhancer elements upstream from the tran-
scriptional initiation site of proinflammatory cytokine
genes [25]. In order to determine if the expression of
E1Blarge alters the translocation of NF-κB to the nucleus,
we analyzed the localization of p65 protein in VIDO R1
(fetal porcine retina cells expressing HAdV-5 E1A +
E1Bsmall)[17] or VR1BL (fetal porcine retina cells express-
ing HAdV-5 E1A + E1Bsmall and PAdV-3 E1Blarge)[19] cells
using immunofluorescene assay. As seen in Fig. 2A, NF-κB
is predominantly located in the cytoplasm of VIDO R1
cells [17]. As expected, TNF-α treatment translocated NF-
κB to the nucleus of VIDO R1 cells. Similarly, NF-κB is
predominantly located in the cytoplasm of VR1BL [19]
cells (Fig 2B). However, TNF-α treatment did not alter the
cytoplasmic location of NF-κB in VR1BL cells. These
results suggest that the constitutive expression of PAdV-3
E1Blarge is able to inhibit the translocation of NF-κB in
TNF-α treated VR1BL cells.
E1Blarge affects the NF-κB binding to oligonucleotides 
containing NF-κB consensus sequence
In order to investigate the effect of PAdV-3 E1Blarge protein
on binding of NF-κB protein to an oligonucleotide con-
taining the IL-8 NF-κB DNA sequence [26,27], initially,
we analyzed the nuclear extracts from transfected and
nontransfected cells by electrophoretic mobility shift
assay (EMSA). HeLa cells were transfected either with plas-
mid pCDNA3.1 DNA or with plasmid pcDNA3.1-pE1BL
DNA as described above. At 48 h post transfection, the
cells were left untreated or treated with TNF-α for 30 min
before HeLa cell nuclear lysates were prepared as
described previously [28]. The nuclear extracts were ana-
lysed by EMSA using labeled oligonucleotides containing
wild-type NF-κB or mutant NF-κB. The results are shown
in Fig. 3. As expected TNF-α treatment induced the bind-
ing of NF-κB to its consensus binding sequence in nuclear
lysates of the cells transfected with plasmid pCDNA3.1
(panel A I). No such binding was observed following TNF-
α treatment of the cells transfected with pCDNA3.1-
pE1BL. Super shift assays using anti-NF-κB p65 antibodies
demonstrated a supershifted band in the nuclear extractsVirology Journal 2007, 4:60 http://www.virologyj.com/content/4/1/60
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of cells transfected with pCDNA3.1 DNA (panel A II). No
such band could be observed when mutant NF-κB oligo-
nucleotides were used as a probe with the nuclear extracts
of the cells transfected with pCNDA3. or pCDNA3.1-
pE1BL DNAs (panel A III). To further confirm these
results, swine testicular (ST) cells were infected with wild-
type or mutant PAdV-3s. At 6 h post infection, the infected
cells were collected and the nuclear cell extracts prepared
as described above. The nuclear extracts were analyzed by
EMSA using wild-type or mutant NF-κB probe. As
expected, NF-κB binding to oligonucleotides containing
NF-κB consensus sequence could be detected in the
nuclear extracts of the cells infected with PAV227 (Panel
BI). No such binding could be detected when mutant NF-
κB sequence was used with the nuclear extracts in EMSA
(Panel BII). These results confirmed that E1Blarge (panel C)
mediated the inhibition of NF-κB translocation to the
nucleus of the cell, hence preventing the NF-κB binding to
NF-κB consensus sequences in the nucleus.
Conclusion
In summary, we have demonstrated that PAdV-3 E1Blarge
protein downregulates the induction of proinflammatory
cytokine IL-8 by inhibiting the NF-κB dependent gene
transcription from human IL-8 promoter. Moreover,
immunofluorescence and EMSA data suggest that the
E1Blarge protein inhibits the nuclear translocation of NF-
κB by interacting with NF-κB. One possible mechanism of
E1Blarge action could be to act as IκB homolog and retain
the ability to bind, and inactivate NF-κB. Interestingly,
PAdV-3 E1Blarge shows 20% identical and 38% homology
(Fig. 4) at the amino acid level to porcine IκB protein
PAdV-3 E1Blarge inhibit IL-8 production Figure 1
PAdV-3 E1Blarge inhibit IL-8 production. (A) Total RNA isolated at 6 h post infection of HeLa cells with indicated viruses 
was analyzed by RNA protection assay using RiboQuant Multi-Probe template set hCK-5. The protected band indicated by the 
label on the right migrate faster that undigested probes, as expected.(B).HeLa cells transfected with the human IL-8 promoter 
containing a NF-κB recognition sequence, cloned upstream from a luciferase reporter cDNA in the presence of plasmid 
pCDNA3.1 or pCDNA3.1-pE1BL were assayed for luciferase activity (expressed as relative light units [RLU]). The error bars 
represent the standard error of mean of triplicate samples.
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(GenBank Accession # A38490). Similar homology is
reported between African swine fever virus encoded IκB
(A238L) protein and porcine IκB protein [29]. Alterna-
tively, the nuclear localization of E1Blarge [19] could have
direct inhibitory effect on IL-8 transcription. These results
suggest that the construction of adenovirus vectors to
include E1Blarge expression cassettes will improve the effi-
cacy and safety of such vectors.
Methods
Viruses and cells
Recombinant PAdV-3 bearing deletions in the E1 region
were generated as described previously [20]. PAV211 con-
tains deletions in the E1A + E3 regions, PAV212 contains
deletions in the E1Bsmall + E3 regions, PAV227 contains
deletions in E1 + E3 regions and PAV300 contains dele-
tion in E3 region. Viruses were propagated and titrated as
described [19,20,24]. HeLa cells were maintained in Dul-
becco's modified Eagle's medium (DMEM) containing
10% fetal calf serum (FCS).
RNase protection assays. Monolayers of HeLa cells (1X105/
well) in 12 well plate were infected with wild-type or
mutant PAdV-3s at a MOI of 100. At 6 h post infection,
HeLa cells were harvested and processed for total RNA
using TRIZOL (Invitrogen) as per manufacturer's proto-
col. RNase protection assay was performed with the Ribo-
Quant Multi-Probe template (BD Biosciences) set hCK-5
as per manufacturer's protocol. Autoradiographs were
analyzed by phosphoimaging with a Personal FX phos-
phoimager and Quantity One software (Bio-Rad).
Expression of NF-κB Figure 2
Expression of NF-κB. The cells constitutively expressing (VR1BL) or not expressing (VIDO R1) PAdV-3 E1Blarge were 
treated with TNF-α. After 15 min, the cells were fixed with 100% methanol and analyzed by indirect immunostaining with anti- 
NF-κB p65 antibody followed by Cy™ conjugated goat anti-mouse secondary antibody. Finally, the cells were incubated with 
DAPI and visualized using Zeiss AxioVision microscope. (A) VIDO R1 cells, (B) VR1BL cells. DAPI (blue); NF-κB p65 (red).
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Plasmid construction
The 181-bp human IL-8 promoter sequence (-135 to +46)
was PCR amplified from the genomic DNA [26,27]
derived from HeLa cells using the primers: hIL8 (-135)
Fw: 5'-CAATGCTAGCG AAGTGTGATGACTCAGG TT-3',
which contains a NheI restriction enzyme site (bold let-
ters), and hIL8 (+46) Bw: 5'-CGTTCTCGAGA AGCTTGT-
GTGCTCTGCTGT-3' containing a XhoI restriction enzyme
site (bold letters). The PCR product was digested with
NheI-XhoI and ligated to NheI-XhoI digested plasmid
pGL3-Basic (Promega) creating plasmid phIL8-Luc. The
plasmid phIL8-Luc contains luciferase gene under the
control of IL-8 promoter. Similarly, the coding region of
E1Blarge gene was PCR amplified using the primers: [PE1BL
(NheI) Fw: 5'-CAGTGCTAGCATGTTCCCTGC TGGAG-
GCGC-3', which contains a NheI restriction enzyme site
(bold letters), and PE1BL (XhoI) Bw: 5'-GTCA CTC-
GAGTC AGTCATC G TCATCGCTGAA-3' containing a
XhoI restriction enzyme site (bold letters)] and PAdV-3
genomic DNA as a template. The PCR product was
digested with NheI-XhoI and ligated to NheI-XhoI
digested plasmid pCDNA3.1(-) (Invitrogen) creating plas-
mid pCDNA3.1-pE1BL. The plasmid pCDNA3.1-pE1BL
contains E1Blarge  gene under the control of human
cytomegalovirus immediate early (HCMV IE) promoter.
Luciferase assay
HeLa cells (1x105 cells/well) were plated in 12-well plate
and incubated overnight. Tansfections were carried out
using 0.5 μg of each plasmid [(phIL8-Luc, pCDNA3.1-
EMSA of nuclear extracts Figure 3
EMSA of nuclear extracts. (A). Nuclear extracts from the plasmid transfected cells (I, II, III) incubated with radiolabeled 
oligonucleotide probe(s) containing wild-type (I, II) or mutant (III) NF-κB motif from human IL-8 promoter [30] with (II) or 
without (I) immunoprecipitation with anti- NF-κB p65 serum. (B) Nuclear extracts from mock infected or virus infected cells 
containing wild-type (I) or mutant (II) NF-κB motif from human IL-8 promoter. (C) Schematic diagram showing deletion of the 
regions in PAV211, PAV212 and PAV227 [19,20].
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pE1BL] or [phIL8-Luc, pCDNA3.1])/well (in triplicate)
using 5 μl of lipofectin (Invitrogen), followed by incuba-
tion for 5 h in Opti-MEM (Invitrogen). After adding FCS
to each well to give a final concentration of 1%, the cells
were incubated for 18 h at 37°C. Finally, the cells were
washed with PBS and lysed in 200 μl of 1x lysis buffer
(Luciferase reporter assay kit, BD Bioscience). Luciferase
activity was determined using 50 μl of cell extract and was
read using a TD-20/20 luminomitor (Turner Designs).
Immunofluorescent Microscopy
VIDO R1 [17] and VR1BL [19] cells plated on glass cover-
slips were untreated or treated with 10 ng/ml TNF-α (R&D
System). At 15 min post treatment, the cells were washed
with PBS, fixed and permeabilized by incubating with
methanol/acetone (1:1) at -20°C for 15 min. The cells
were rehydrated with PBS and incubated for 1 hour in a
1:200 dilution of monoclonal antibody specific for the
p65 subunit of NF-κB factor (Santa Cruz). The cells were
washed three times with PBS and incubated with 1: 800
diluted Cy3-labeled goat anti-mouse antibody (Jackson
Laboratory) for 30 min at room temperature. Finally, the
cells were washed three times in PBS before incubating
with DAPI at concentration of 1μg/ml (Roche) for 5 min.
Fluorescence was examined and photographed using a
Carl Zeiss Axiovert 200 M inverted fluorescent micro-
scope.
Homology of E1Blarge to IκBα Figure 4
Homology of E1Blarge to IκBα. Alignment of porcine IκBα (pIκB; GenBank Accession # A38490) and PAdV-3 E1Blarge 
(pE1BL: GenBank Accession # AF083132). Shaded residues are identical between pIκB and pE1BL. Lines shown above denote 
the five repeats of ankyrin consensus sequence in IκBα.
  PIkB  MF------------------QPAEPGQ----------EWAME---GPRDA   19 
 pE1BL  MFPAGGANDGGAGAAGAVHHQDAERGAGDAVAQWVIRQWQRGRDAGPGGA   50
  pIkB  LK---------------KERLLDDRHDSGLDSMKD---------EE----   41 
 PE1BL  QAPAGAGRGGGGRGWDGSERAQARRAGSGLDRRRPGGAGGEGSGEEAGGS  100 
  pIkB  ----YEQMVKELREIRLEPQEAPRGAEPWKQQLTEDGDSFLHLAIIHEE-   86 
 pE1BL   SMVSYQQVLSEYLESPLEMHER-YSFEQIRPYMLQPGDDLGEMIAQHAKV  149 
  pIkB  -----------KALTMEVVRQVKGDLAFLNFQNNLQQ----TPL-HLAVI  120 
 pE1BL  ELQPGTVYELRRPITIRSMCYIIGNGAKIKIRGNYTEYINIEPRNHMCSI  199 
  pIkB  TNQPEIAEALLEAGCDPELRDFRG----NTP—-LHLACEQGCLASV----  160 
 pE1BL   AGMWSV—-TITDVVFDRELPARGGLILANTHFILHGCNFLGFLGSVITAN  247 
  pIkB  --GVLTQPRGTQHLHSILQATNYNGHTCLHLASIHGYLGIVELLVSLG-A  207 
 pE1BL   AGGVV---RGC-YFFACYKALDHRGRLWL-TVNENTFEKCVYAVVSAGRC  292 
  pIkB  DNVAQEPCNGRTALHLA---------------------VDL---QNPDLV  233 
 pE1BL  RIKYNSSLSTFCFLHMSYTGKIVGNSIMSPYTFSDDPYVDLVCCQSGMVM  342 
  pIkB  SLLLKCGADVNRVTYQ-------------------GYSPYQLTWGRPSTR  264 
 pE1BL     PLSTVHIAPSSRLPYPEFRKNVLLRSTMFVGGRLGSFSPSRCSYSYSSLV 392 
  
  pIkB  IQQQLGQ---------LTLENLQMLPESE-DEESYDTESEFT---EDELP  301 
 pE1BL  VDEQSYRGLSVTCCFDQTCEMYKLLQCTEADEMETDTSQQYACLCGDNHP  442 
  pIkB  YD--------DCVLGGQRLTL-----------          314 
  pE1BL  WPQVRQMKVTDALRAPRSLVSCNWGEFSDDDD         474 Virology Journal 2007, 4:60 http://www.virologyj.com/content/4/1/60
Page 7 of 8
(page number not for citation purposes)
Electrophoretic mobility shift assays (EMSA)
HeLa nuclear lysates were prepared as described previ-
ously ([28]. Briefly, the cells were washed two times with
phosphate-buffered saline, resuspended in 4 pellet vol-
umes of buffer A [(10 mM TRIS (pH 7.9), 10 mM NaCl,
1.5 mM MgCl2, 5 mM dithiothreitol (DTT), 0.5 mM phe-
nyl-methyl sulfanyl fluoride (PMSF), and 5 μg of apro-
tinin, leupeptin, and pepstatin (ALP) per ml)] and
incubated at 4°C for 1 h. The cells were lysed by three
freeze/thaw cycles and centrifuged for 5 min at 2000 × g at
4°C. The nuclei were washed once with buffer A, resus-
pended in 3 pellet volumes of buffer B [(20 mM TRIS (pH
7.9), 20% glycerol, 400 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA, 5 mM DTT, 0.5 mM PMSF, and 5 μg of ALP per
ml)] and incubated at 4°C for 30 min. The nuclear lysates
were collected after centrifugation for 30 min at 12,000 ×
g at 4°C and stored at -80°C. The oligonucleotides con-
taining wild-type NF-κB (shown in boldface) motif (5'-
CGTAGCCATCAGTTGCAAA TCGTGGAATTTCCTCT-3')
or mutant NF-κB (mutated residues underlined) motif
(5'CTAGGCCATCAGTTGCAAATCGTTTAATTTAATCT)
[30] were end-labeled with [α-32P] dCTP using the Kle-
now fragment of DNA Polymerase I.
Each binding reaction was assembled on ice containing
0.2 ng of double-stranded labeled probe, 10 μg of HeLa
nuclear lysate from indicated samples, 0.5 μg poly(dI-
dC), 10 mM Tris (pH 7.8), 50 mM NaCl, 1 mM EDTA and
3.3 mM sodium acetate. DNA-protein complexes were
electrophoresed for 2 h at 150 V through 5% acrylamide
gels. The gels were dried for 60 min at 80°C and exposed
to Phosphor screens. Images were analyzed with a Molec-
ular phosphoimager FX and the Quantity One software
package (BIO – RAD).
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